Return to search

Characterization of Iron Oxide Nanoparticle-Based Contrast Agent in Photoacoustic Imaging and Magnetic Resonance Imaging / Karaktärisering av järnoxid-nanopartikel som kontrastmedel för fotoakustisk avbildning och magnetresonanstomografi

Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult type of cancer to treat, due to late diagnosis which is a result of vague symptoms and lack of biomarkers, as well as refractory behavior toward current treatment protocols. Imaging of the disease progression therefore plays a crucial role in identifying potentially curable PDAC patients at an early stage. Nanoparticle-based contrast agents have shown multimodal capabilities and potential to enhance the contrast of previously undetectable pathological changes, including PDAC. In this master’s thesis study, an iron oxide nanoparticle (IONP) was evaluated as a potential multimodal contrast agent for both photoacoustic imaging (PAI) and magnetic resonance imaging (MRI). The investigated particle was composed of Fe3O4 with a hydrodynamic size of 418.5 nm and a zeta potential of -27.7 mV. In the agarose suspended IONP phantom studies, the IONP demonstrated a two-fold higher T2 contrast compared to commercial IONP VivoTrax (Magnetic Insight), as well as generating strong and stable photoacoustic signal throughout the first near-infrared window (700 to 1000 nm). Based on this thesis’ proof of concept study, Fe3O4 IONP showed good potential as multimodal contrast agent for MRI and PAI. Future work consists of modification of the particle composition and in vivo imaging on animals to evaluate the application in PDAC diagnostics.

Identiferoai:union.ndltd.org:UPSALLA1/oai:DiVA.org:kth-297596
Date January 2021
CreatorsZheng, Jimmy
PublisherKTH, Skolan för kemi, bioteknologi och hälsa (CBH)
Source SetsDiVA Archive at Upsalla University
LanguageEnglish
Detected LanguageEnglish
TypeStudent thesis, info:eu-repo/semantics/bachelorThesis, text
Formatapplication/pdf
Rightsinfo:eu-repo/semantics/openAccess
RelationTRITA-CBH-GRU ; 2021:083

Page generated in 0.0017 seconds